靶向治疗联合同步放化疗治疗晚期非小细胞肺癌患者的临床效果观察

目的分析靶向治疗联合同步放化疗治疗晚期非小细胞肺癌患者的临床效果。方法162例晚期非小细胞肺癌患者,采用随机数字表法分为对照组和研究组,各81例。对照组采用同步放化疗治疗,研究组采用靶向治疗联合同步放化疗治疗。比较两组患者临床疗效、毒副作用发生情况及治疗前后癌症患者生存质量核心量表(EORTCQLQ-C30)评分。结果研究组客观缓解率(ORR)65.43%、疾病控制率(DCR)95.06%均高于对照组的46.91%、85.19%,差异具有统计学意义(P<0.05)。研究组毒副作用发生率为17.28%(14/81),低于对照组的39.51%(32/81),差异有统计学意义(P<0.05)。治疗后,两组EORTCQLQ-C30评分均高于治疗前,且研究组EORTCQLQ-C30评分(75.41±7.86)分高于对照组的(64.85±6.85)分,差异有统计学意义(P<0.05)。结论对晚期非小细胞肺癌患者应用靶向治疗联合同步放化疗治疗可获得更显著的治疗效果,且毒副作用小,明显改善患者治疗后生活质量。

Observation on clinical effect of targeted therapy combined with concurrent chemoradiotherapy in the treatment of advanced non-small cell lung cancer

Objective To analyze the clinical effect of targeted therapy combined with concurrent chemoradiotherapy in the treatment of advanced non-small cell lung cancer.Methods A total of 162 patients with advanced non-small cell lung cancer were divided into control group and research group by random numerical table,with 81 cases in each group.The control group was treated with concurrent chemoradiotherapy,and the research group was treated with targeted therapy in combination with concurrent chemoradiotherapy.The clinical efficacy,occurrence of toxic side effects and European organization for research and treatment of cancer quality of life core questionnaire(EORTCQLQ-C30)scores before and after treatment were compared between the two groups.Results The objective response rate(ORR)65.43%and the disease control rate(DCR)95.06%of the research group were higher than 46.91%and 85.19%of the control group,and the difference was statistically significant(P<0.05).The incidence of toxic side effects of the research group was 17.28%(14/81),which was lower than 39.51%(32/81)in the control group,and the difference was statistically significant(P<0.05).After treatment,the EORTCQLQ-C30 score of the two groups were higher than those before treatment,and the EORTCQLQ-C30 score(75.41±7.86)points was higher than(64.85±6.85)points of the control group.All the differences were statistically significant(P<0.05).Conclusion In the treatment of patients with advanced non-small cell lung cancer,targeted therapy combined with concurrent chemoradiotherapy can obtain more significant therapeutic effects,and has less toxic side effects,which can significantly improve the quality of life of patients after treatment.